NCT Number: NCT01743053
A Pilot Trial of the Use of ReCell® Autologous Cell Harvesting Device for Venous Leg Ulcers
This is a prospective, randomised, open label, controlled pilot study to evaluate the safety and preliminary effectiveness of the ReCell Autologous Cell Harvesting Device (ReCell) for the management of chronic leg ulcers associated with venous insufficiency. Outcome will be compared between study participants receiving standard care (debridement, compression therapy) and participants receiving ReCell in addition to standard care.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Hôpital Lapeyronie, Montpellier, France
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Chronic venous leg ulcer (CEAP Clinical classification of 6)
- Confirmed, actively managed venous reflux
- No exposed tendon or bone
- Ulcer is >4 weeks in duration
- Ulcer surface area between 2cm2 and 80cm2
- ABI ≥ 0.8
- The patient is 18 years of age or older
- The patient is willing to complete all follow-up evaluations required by the study protocol
- The patient is able to abstain from any other treatment of the ulcer for the duration of the study, unless medically necessary
- The patient agrees to abstain from enrolment in any other clinical trial for the duration of the study
- The patient is able to read and understand instructions and give voluntary written informed consent
- The patient is able and willing to follow the protocol requirements (including compression therapy)
- Patients enrolling at any site in France must have an affiliation to a social security scheme
Exclusion criteria
- Study treatment area has exposed bone or tendon
- Poorly controlled diabetes
- Arterial insufficiency (ABI < 0.8)
- Pregnant/lactating females (self-reported or tested, per institutional requirements)
- The patient has an active wound infection requiring antibiotic therapy
- The patient has had a prior surgical treatment of the ulcer within the past 60 days
- The patient has a life expectancy of 1-year or less
- The patient has a severe dermatological disorder (e.g. severe psoriasis, epidermolysis bullosa, pyoderma gangrenosum).
- The patient is unable to follow the protocol
- The patient is taking, or has taken in the past 60 days, mycophenolate mofetil or >10mg of corticosteroids per day.
- The patient has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives
- The patient has a known hypersensitivity to trypsin or Compound Sodium Lactate for Irrigation (Hartmann's) solution.
- The patient is a vulnerable or protected adult.
- The patient is unable to provide consent
Treatment and study plan
Standard care
OtherPrimary outcomes
-
Wound healing
Time frame: 12 weeks
The primary objective of the study is to assess the difference in incidence of ulcer closure (investigator assessed as complete epithelialisation without drainage) between the ReCell group and the control group.
Secondary outcomes
-
Wounds characterization/Quality of Life
Time frame: At each follow-up visit (1, 2, 4, 6, 8, 12, 24, 52 weeks)
- Wound area
- Wound volume
- Pain
- Recurrence
- Health-related Quality of Life
-
Dressing Change
Time frame: At each follow-up visit (1, 2, 4, 6, 8, 12, 24, 52 weeks) until healed
- Dressing change
Sponsors and collaborators
Lead sponsor
Avita Medical
Industry
Collaborators
- NAMSA
Registry information
Important dates
- Study start
- 2013
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Dec 6, 2012
- Registry last updated
- Jun 8, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Chemical Debridement and Leg Ulcers
NCT06652360
Cardiovascular Diseases, Leg Ulcer
Eastbourne, United Kingdom
View Trial DetailsA RCT Evaluating Efficacy of Type-I Collagen Skin Substitute vs. Human Amnion Membrane in Treatment of Venous Leg Ulcers
NCT06831760
Cardiovascular Diseases, Leg Ulcer
Mandya, Karnataka, India
View Trial DetailsTopical Timolol Benefit in Venous Ulcers
NCT02422017
Leg Ulcer, Skin Diseases
Amiens, France
View Trial DetailsSingle-Use Negative Pressure Wound Therapy System vs. Traditional Negative Pressure Wound Therapy System (tNPWT)
NCT02470806
Cardiovascular Diseases, Diabetes Complications
Carlsbad, California, United States
View Trial Details